Exelixis (EXEL) – Investment Analysts’ Weekly Ratings Updates

A number of firms have modified their ratings and price targets on shares of Exelixis (NASDAQ: EXEL) recently:

• 7/24/2026 – Exelixis was downgraded by Weiss Ratings from “buy (b+)” to “buy (b)”.
• 7/23/2026 – Exelixis had its price target raised by Morgan Stanley from $50.00 to $53.00. They now have an “equal weight” rating on the stock.
• 7/22/2026 – Exelixis had its “market outperform” rating reaffirmed by Citigroup Inc..
• 7/14/2026 – Exelixis had its price target raised by Barclays PLC from $45.00 to $49.00. They now have an “equal weight” rating on the stock.
• 7/13/2026 – Exelixis had its price target raised by Wells Fargo & Company from $40.00 to $49.00. They now have an “equal weight” rating on the stock.
• 7/8/2026 – Exelixis was upgraded by Weiss Ratings from “buy (b)” to “buy (b+)”.
• 7/7/2026 – Exelixis had its price target raised by Royal Bank Of Canada from $43.00 to $46.00. They now have a “sector perform” rating on the stock.
• 7/7/2026 – Exelixis had its price target raised by Truist Financial Corporation from $54.00 to $56.00. They now have a “hold” rating on the stock.
• 7/2/2026 – Exelixis had its “buy” rating reaffirmed by UBS Group AG.
• 7/2/2026 – Exelixis had its price target raised by UBS Group AG from $43.00 to $52.00. They now have a “neutral” rating on the stock.
• 7/2/2026 – Exelixis had its “buy” rating reaffirmed by HC Wainwright. They now have a $56.00 price target on the stock.
• 6/25/2026 – Exelixis was downgraded by Truist Financial Corporation from “buy” to “hold”. They now have a $54.00 price target on the stock, up from $51.00.
• 6/24/2026 – Exelixis had its price target raised by Citizens Jmp from $50.00 to $55.00. They now have a “market outperform” rating on the stock.
• 6/22/2026 – Exelixis had its “positive” rating reaffirmed by Morgan Stanley.

Insiders Place Their Bets

In other Exelixis news, EVP Patrick J. Haley sold 32,110 shares of Exelixis stock in a transaction on Wednesday, May 20th. The shares were sold at an average price of $49.81, for a total value of $1,599,399.10. Following the completion of the sale, the executive vice president directly owned 357,638 shares of the company’s stock, valued at approximately $17,813,948.78. The trade was a 8.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Jack L. Wyszomierski sold 3,925 shares of the stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $50.55, for a total transaction of $198,408.75. Following the transaction, the director directly owned 284,384 shares in the company, valued at $14,375,611.20. This trade represents a 1.36% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 219,170 shares of company stock valued at $10,620,641. 2.60% of the stock is currently owned by corporate insiders.

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.